In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

1. (Currently amended) A method for delivery of dendritic cells to a secondary lymphoid tissue of a subject, wherein selectin ligand molecules are expressed on cells of the secondary lymphoid tissue, comprising

providing isolated dendritic cells which are genetically modified to express on the cell surface a selectin polypeptide comprising an endothelial selectin ligand binding portion of a selectin selected from the group consisting of L-selectin, E-selectin and P-selectin, and

administering the isolated genetically modified dendritic cells to the subject.

2.-4. (Canceled)

5. (Currently amended) A method for delivery of dendritic cells to a non-lymphoid tissue of a subject where selectin ligands are expressed on endothelial cells of the non-lymphoid tissue, comprising

providing isolated dendritic cells which are genetically modified to express on the cell surface a selectin polypeptide comprising an endothelial selectin ligand binding portion of a selectin selected from the group consisting of L-selectin, E-selectin and P-selectin, and

administering the isolated genetically modified dendritic cells to the subject.

6. (Previously presented) The method of claim 1, wherein the selectin polypeptide consists of a selectin selected from the group consisting of L-selectin, E-selectin and P-selectin.

7. (Previously presented) The method of claim 1, wherein the step of providing isolated dendritic cells comprises isolating dendritic cells from the subject and transfecting the isolated dendritic cells with a nucleic acid molecule which encodes the selectin polypeptide.

8.-11. (Canceled)

12. (Previously presented) The method of claim 1, wherein the step of providing isolated dendritic cells further comprises treating the isolated transfected dendritic cells with isolated activated platelets or membrane microparticles thereof which contain P selectin.

13. (Previously presented) The method of claim 1, wherein the isolated dendritic cells are administered intravenously.

14. (Currently amended) A method for delivery of dendritic cells to a secondary lymphoid tissue of a subject, wherein selectin ligand molecules are expressed on cells of the secondary lymphoid tissue, comprising

providing isolated dendritic cells,

treating the isolated dendritic cells with isolated activated platelets or membrane microparticles thereof which contain P selectin to form platelet modified dendritic cells, and

administering the isolated platelet modified dendritic cells to the subject.

15.-17. (Canceled)

18. (Currently amended) A method for delivery of dendritic cells to a non-lymphoid tissue of a subject where selectin ligands are expressed on endothelial cells of the non-lymphoid tissue, comprising

providing isolated dendritic cells,

treating the isolated dendritic cells with isolated activated platelets or membrane microparticles thereof which contain P selectin to form platelet modified dendritic cells, and

administering the isolated platelet modified dendritic cells to the subject.

19. (Previously presented) The method of claim 14, wherein the step of providing isolated dendritic cells further comprises culturing the isolated dendritic cells to expand the isolated dendritic cells.

20. (Previously presented) The method of claim 14, wherein the isolated platelet modified dendritic cells are administered intravenously.

21. (Currently amended) A method for delivery of dendritic cells to a secondary lymphoid tissue of a subject, wherein selectin ligand molecules are expressed on cells of the secondary lymphoid tissue, comprising

providing isolated dendritic cells,

providing isolated activated platelets or membrane microparticles thereof which contain P selectin,

administering the isolated dendritic cells and the isolated activated platelets or membrane microparticles thereof to the subject, wherein the isolated activated platelets or membrane microparticles thereof are administered prior to or concurrently with the isolated dendritic cells.

22.-24. (Canceled)

25. (Currently amended) A method for delivery of dendritic cells to a non-lymphoid tissue of a subject where selectin ligands are expressed on endothelial cells of the non-lymphoid tissue, comprising

providing isolated dendritic cells,

providing isolated activated platelets or membrane microparticles thereof which contain P selectin,

administering the isolated dendritic cells and the isolated activated platelets or membrane microparticles thereof to the subject, wherein the isolated activated platelets or membrane microparticles thereof are administered prior to or concurrently with the isolated dendritic cells.

26.-27. (Canceled)

28. (Previously presented) A composition comprising isolated dendritic cells which are genetically modified to express on the cell surface a selectin polypeptide comprising an endothelial selectin ligand binding portion of a selectin selected from the group consisting of L-selectin, E-selectin and P-selectin.

29. (Original) The composition of claim 28, wherein the selectin polypeptide consists of a selectin selected from the group consisting of L-selectin, E-selectin and P-selectin.

30. (Previously presented) The composition of claim 28, wherein the amount of the selectin polypeptide expressed on the cell surface is greater than the naturally occurring amount of the selectin expressed on the cell surface *in vitro* and is sufficient to target the genetically modified dendritic cells to peripheral lymph nodes.

31.-35. (Canceled)

36. (Original) A composition comprising isolated dendritic cells and isolated activated platelets or membrane microparticles thereof which contain P selectin.

37. (Currently amended) A ~~vaccine~~ composition comprising the composition of claim 28 and an antigen.

38.-47. (Canceled)

48. (Currently amended) A method for stimulating an immune response to an antigen in a subject comprising

administering to the subject the ~~vaccine~~ composition of claim 37.

49.-50. (Canceled)